A Phase 2 interventional study of SAR441344 and Placebo in Sjögren's Syndrome and Sjogren's Syndrome, sponsored by Sanofi. Completed at 36 sites in 12 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-10-09.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Sjogren's Syndrome with a site in France — 18 open to participants now, 25 under way, 7 of them phase 3. Sjogren's Syndrome · France.
Among the 58 studies in Sjogren's Syndrome with a site in France, this one is the 28th largest by enrollment of the 40 interventional ones that give a count, is one of 7 that started in 2020, is one of 14 in phase 2, and was the 24th registered.
330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.
Browse Sjogren's Syndrome studies →18 of the 58 studies in Sjogren's Syndrome with a site in France are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in France, United States, Australia and 6 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in France, United States, Australia and 17 more countries
Ages 18+
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
GlaxoSmithKline · Sites in France, Argentina, Brazil and 6 more countries
Ages 18–70
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 10 · Phase 4 1
First in 2008; this study’s year is marked. 7 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 50 across 218 interventional studies indexed under Sjogren's Syndrome.
Median enrollment 169 across the 40 interventional studies, 106 across the 18 observational. Of the 26 that completed or were terminated, 9 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 58 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 1 study filed under Sjogren's Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Sjogren's Syndrome with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05946941Phase 3Bristol-Myers SquibbA Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | 2026-11-18 |
| NCT06741969Phase 3Janssen Research & Development, LLCNipocalimab in Moderate to Severe Sjogren's Disease | 2027-02-04 |
| NCT06875102Centre Hospitalier Universitaire de Saint EtienneFatigue in Sjögren's Syndrome: 3 Therapeutic Strategies | 2027-04 |
| NCT06842316Centre Hospitalier Régional d'OrléansEffects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases | 2027-04-09 |
| NCT03003572Centre Hospitalier Universitaire de Saint EtienneAutoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 58 studies in Sjogren's Syndrome with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the therapeutic efficacy of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with primary Sjögren's syndrome (pSjS), assessed by the change of the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI)
Secondary Objectives:
This is a multicenter, randomized, double blind, placebo controlled, parallel group proof of concept Phase 2 study to evaluate the therapeutic efficacy of SAR441344 in adult patients with primary Sjögren's syndrome (pSjS), as well as safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Active life threatening or organ threatening complications of pSjS disease at the time of Screening based on treating physician evaluation including but not restricted to:
Participants treated with the following medications/procedures prior to Screening:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SAR441344 single intravenous (IV) loading dose on Day 1 followed by a single subcutaneous (SC) dose administered once every 2 weeks from Week 2 to Week 10 (5 administrations)
Drug: SAR441344
Matching placebo
Drug: Placebo
Pharmaceutical form: solution for injection Route of administration: intravenous or subcutaneous
Pharmaceutical form: solution for injection Route of administration: intravenous or subcutaneous
Change From Baseline to Week 12 in ESSDAI Score
ESSDAI is validated and established outcome measurement for therapeutic efficacy in Sjögren's syndrome, evaluating disease activity mainly on extra-glandular manifestations. This score consists of 12 organ-specific domains (constitutional, lymphadenopathy, glandular, articular, cutaneous, pulmonary, renal, muscular, peripheral and central nervous system, hematological, biological), which are scored based on organ-specific items in 3 to 4 different severity grades (no, low, moderate, high; with 0=no and 3=high). These scores are summed up over all 12 domains in weighted way (severity grades are multiplied with weights ranging 1-6 depending on domain) to summarize into total score(0-123). Higher scores indicates worse outcome. Negative change from baseline indicates improvement. Baseline=Day 1 assessment value. Least squares (LS) mean is calculated using mixed models for repeated measures (MMRM). Observed values after occurrence of intercurrent events are excluded.
Time frame: Baseline (Day 1) to Week 12
Change From Baseline to Week 12 in European League Against Rheumatism (EULAR) Sjögren's Syndrome Patient Reported Index (ESSPRI) Score
The ESSPRI is a validated and established outcome measurement, reported by participants, which rates the key disease manifestations: fatigue, dryness, and pain, based on a numeric scale ranging from 0 to 10, where 0 is defined as no symptoms and 10 as maximum imaginable complaints. The total score is the mean score of the 3 scales and ranges from 0 to 10. Higher scores indicates worse outcome. A negative change from baseline indicates improvement. Baseline is defined as Day 1 assessment value. LS mean is calculated using MMRM. Observed values after occurrence of intercurrent events are excluded.
Time frame: Baseline (Day 1) to Week 12
Change From Baseline to Week 12 in Multidimensional Fatigue Inventory (MFI) General Fatigue Subscale and Other Subscales Score
The MFI is a validated, 20 item self-report instrument to evaluate fatigue by investigating the following subscales: general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. Each subscale consists of 4 items that are scored using a scale from 1 ("yes, this is true") to 5 ("no, this is not true") on which the participants indicate how the listed statements applied to their current fatigue situation. Item scores are summed to create individual subscale score ranging from 4 to 20. A higher score indicates a higher degree of fatigue. A negative change from baseline indicates improvement. Baseline is defined as Day 1 assessment value. LS mean is calculated using ANCOVA. Observed values after occurrence of intercurrent events are excluded.
Time frame: Baseline (Day 1) to Week 12
Mean Plasma Concentration of SAR441344
Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344.
Time frame: At end of infusion and 4 hours post-infusion on Day 1; pre-dose at Weeks 2, 4, 6, 8, 10, and at Week 12
Median Plasma Concentration of SAR441344
Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344.
Time frame: At end of infusion and 4 hours post-infusion on Day 1; pre-dose at Weeks 2, 4, 6, 8, 10, and at Week 12
Maximum Plasma Concentration (Cmax) of SAR441344
Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344. Cmax was assessed by a Bayesian approach using the population PK model.
Time frame: After the last SC dose on Week 10 up to 336 hours post-dose
Time to Maximum Plasma Concentration (Tmax) of SAR441344
Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344. tmax was assessed by a Bayesian approach using the population PK model.
Time frame: After the last SC dose on Week 10 up to 336 hours post-dose
Area Under the Curve Over the Dosing Interval (AUC0-tau) of SAR441344
Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344. AUC0-tau was assessed by a Bayesian approach using the population PK model.
Time frame: After the last SC dose on Week 10 up to 336 hours post-dose
Terminal Half-life (t1/2z) of SAR441344
Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344. t1/2z was assessed by a Bayesian approach using the population PK model.
Time frame: Week 10 to Week 12
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and Adverse Events of Special Interest (AESI)
An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. TEAEs: AEs that occurred, worsened, or became serious during the TEAE period (time from the first IMP administration up to Week 24). Serious adverse events (SAE): Any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or was a congenital anomaly/birth defect. An AESI: an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required.
Time frame: From first dose of IMP (Day 1) up to end of follow-up period (Week 24)
Number of Participants With Treatment Discontinuation and Withdrawals Due to TEAEs
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. TEAEs were AEs that occurred, worsened, or became serious during the TEAE period (time from the first IMP administration up to Week 24).
Time frame: From first dose of IMP (Day 1) up to end of follow-up period (Week 24)
Number of Participants With Increase in Pain Intensity Compared to Pre-dose Pain Intensity at Injection Site by Verbal Descriptor Scale (VDS)
For the measurement of local tolerability, participants had a self-evaluation using a VDS before IMP administration, after completion of the IMP administration, and 2 hours post-administration. The participants were asked to report sensations at the injection site and rated the pain severity as following grading: 0= no pain; 1= mild pain; 2= moderate pain, 3= severe pain, 4= very severe. A positive change in VDS score indicated a higher pain severity compared to the pre-dose pain. The numerical change provides the number of grades the pain got worse (positive change) or improved (negative change). Total number of participants with pain intensity increase (change in VDS score of greater than or equal to 1) compared to pre-dose pain intensity are reported.
Time frame: Pre-dose (within 24 hours prior IMP dosing), post-dose (up to 15 minutes after dosing) and 2 hours post-dose at Weeks 2, 4, 6, 8 and 10
Number of Participants With AEs Related to Local Tolerability Findings
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. Local tolerability at injection site was assessed following IMP injection and findings at the site of injection such as injection site erythema, injection site reaction, and injection site pain were recorded.
Time frame: Baseline (Day 1) to Week 10
Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Vital Signs
PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Sitting systolic blood pressure (SSBP) less than or equal to (≤)95 millimeters of mercury (mmHg) and decrease from baseline ≥20 mmHg; ≥160 mmHg and increase from baseline ≥20 mmHg; Sitting diastolic blood pressure (SDBP) ≤45 mmHg and decrease from baseline ≥10 mmHg, ≥110 mmHg and increase from baseline ≥10 mmHg; Sitting heart rate (HR) ≤50 beats per minute (bpm) and decrease from baseline ≥20 bpm, ≥120 bpm and increase from baseline ≥20 bpm; Weight ≥5% decrease from baseline, ≥5% increase from baseline.
Time frame: Baseline (Day 1) to Week 24
Number of Participants With PCSA in Electrocardiogram
PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: HR \<50 bpm, \<40 bpm, \>90 bpm, \>90 bpm and increase from baseline ≥20 bpm, \>100 bpm; PR interval, aggregate \>200 milliseconds (msec), \>200 msec and increase from baseline ≥25%, \>220 msec, \>220 msec and increase from baseline ≥25%, \>240 msec, \>240 msec and increase from baseline ≥25%; QRS duration, aggregate \>110 msec, \>110 msec and increase from baseline ≥25%, \>120 msec, \>120 msec and increase from baseline ≥25%; QT interval, aggregate \>500 msec; corrected QT (QTc) correction method unspecified \>450 msec, \>480 msec, increase from baseline \[30-60\] msec, increase from baseline \>60 msec.
Time frame: Baseline (Day 1) to Week 24
Number of Participants With PCSA in Hematology Parameters
PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Hemoglobin (Hb) ≤115 grams per liter (g/L) (Male \[M\]) or ≤95 g/L (Female \[F\]), ≥185 g/L (M) or ≥165 g/L (F), decrease from baseline ≥20 g/L; Hematocrit ≤0.37 volume per volume (v/v) (M) or ≤0.32 v/v (F), ≥0.55 v/v (M) or ≥0.5 v/v (F); Erythrocytes (red blood cells \[RBC\]) ≥6 x 10\^12 per liter (/L); Platelets \<100 x 10\^9/L, ≥700 x 10\^9/L; Leukocytes (white blood cells \[WBC\]) \<3 x 10\^9/L (Non-Black\[NB\]) or \<2 x 10\^9/L (Black\[B\]), ≥16 x 10\^9/L; Neutrophils \<1.5 x 10\^9/L (NB) or \<1 x 10\^9/L (B); Lymphocytes \>4 x 10\^9/L, \<0.5 x 10\^9L; Monocytes \>0.7 x 10\^9/L; Basophils \>0.1 x 10\^9/L; Eosinophils \>0.5 x 10\^9/L or \>upper limit of normal(ULN) (if ULN ≥0.5 x 10\^9/L).
Time frame: Baseline (Day 1) to Week 24
Number of Participants With PCSA in Clinical Chemistry Parameters
PCSA values:abnormal values considered medically important by Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by Sponsor.Criteria for PCSA:Sodium≤129 millimoles per liter(mmol/L),≥160 mmol/L;Potassium\<3 mmol/L,≥5.5 mmol/L;Glucose≤3.9 mmol/L and \<lower limit of normal(LLN),≥11.1 mmol/L(unfasted);≥7 mmol/L(fasted); Creatine kinase(CK)\>3 ULN,\>10 ULN;Creatinine≥150 micromoles/L(adults),≥30% change from baseline,≥100% change from baseline;Creatinine clearance(CG)≥60-\<90 milliliters per minute(mL/min)(mild decrease in glomerular filtration rate\[GFR\]),≥30-\<60 mL/min(moderate decrease in GFR),≥15-\<30 mL/min(severe decrease in GFR),\<15 mL/min(end stage renal disease),Urea nitrogen≥17 mmol/L;Alkaline phosphatase(ALP)\>1.5 ULN;Alanine aminotransferase(ALT)\>3 ULN; ALT\>3 ULN and bilirubin\>2 ULN;Aspartate aminotransferase(AST)\>3 ULN;Direct bilirubin\>35% bilirubin and bilirubin\>1.5 ULN;Total bilirubin\>1.5 ULN,\>2 ULN.
Time frame: Baseline (Day 1) to Week 24
Number of Participants With PCSA in Urinalysis Parameters
PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Potential of hydrogen (pH) ≤4.6 or ≥8.
Time frame: Baseline (Day 1) to Week 24
Number of Participants With Anti-drug Antibodies (ADA) to SAR441344
Serum samples were collected at the specified timepoints for the assessment of ADAs to SAR441344. Number of participants with treatment-emergent ADA defined as at least 1 treatment-induced/boosted ADA during the treatment-emergent period, i.e. from the time of the IMP administration up to the end of study visit are reported. Number of participants with positive ADA are reported.
Time frame: Baseline, Week 4, Week 8, Week 12, and Week 24
The study was conducted at 35 centers in 12 countries. A total of 234 participants were screened from 12 November 2020 to 10 August 2023, of which 150 were screen failures. Screen failures were mainly due to not meeting the eligibility criteria.
| Milestone | Placebo | SAR441344 |
|---|---|---|
| Started | 42 | 42 |
| Completed | 39 | 40 |
| Not completed | 3 | 2 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 |
ESSDAI is validated and established outcome measurement for therapeutic efficacy in Sjögren's syndrome, evaluating disease activity mainly on extra-glandular manifestations. This score consists of 12 organ-specific domains (constitutional, lymphadenopathy, glandular, articular, cutaneous, pulmonary, renal, muscular, peripheral and central nervous system, hematological, biological), which are scored based on organ-specific items in 3 to 4 different severity grades (no, low, moderate, high; with 0=no and 3=high). These scores are summed up over all 12 domains in weighted way (severity grades are multiplied with weights ranging 1-6 depending on domain) to summarize into total score(0-123). Higher scores indicates worse outcome. Negative change from baseline indicates improvement. Baseline=Day 1 assessment value. Least squares (LS) mean is calculated using mixed models for repeated measures (MMRM). Observed values after occurrence of intercurrent events are excluded.
| score on a scale | Placebo | SAR441344 |
|---|---|---|
| Change From Baseline to Week 12 in ESSDAI Score | -5.60 ± 0.60 | -5.29 ± 0.59 |
The ESSPRI is a validated and established outcome measurement, reported by participants, which rates the key disease manifestations: fatigue, dryness, and pain, based on a numeric scale ranging from 0 to 10, where 0 is defined as no symptoms and 10 as maximum imaginable complaints. The total score is the mean score of the 3 scales and ranges from 0 to 10. Higher scores indicates worse outcome. A negative change from baseline indicates improvement. Baseline is defined as Day 1 assessment value. LS mean is calculated using MMRM. Observed values after occurrence of intercurrent events are excluded.
| score on a scale | Placebo | SAR441344 |
|---|---|---|
| Change From Baseline to Week 12 in European League Against Rheumatism (EULAR) Sjögren's Syndrome Patient Reported Index (ESSPRI) Score | -2.21 ± 0.34 | -1.92 ± 0.34 |
The MFI is a validated, 20 item self-report instrument to evaluate fatigue by investigating the following subscales: general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. Each subscale consists of 4 items that are scored using a scale from 1 ("yes, this is true") to 5 ("no, this is not true") on which the participants indicate how the listed statements applied to their current fatigue situation. Item scores are summed to create individual subscale score ranging from 4 to 20. A higher score indicates a higher degree of fatigue. A negative change from baseline indicates improvement. Baseline is defined as Day 1 assessment value. LS mean is calculated using ANCOVA. Observed values after occurrence of intercurrent events are excluded.
| score on a scale | Placebo | SAR441344 |
|---|---|---|
| General Fatigue Scale Score | 0.37 ± 0.30 | -0.18 ± 0.30 |
| Mental Fatigue Scale Score | 0.26 ± 0.36 | 0.37 ± 0.36 |
| Physical Fatigue Scale Score | 0.27 ± 0.36 | -0.30 ± 0.36 |
| Reduced Activity Scale Score | 0.22 ± 0.31 | 0.29 ± 0.31 |
| Reduced Motivation Scale Score | 0.30 ± 0.30 | 0.26 ± 0.29 |
Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344.
| microgram per milliliter (mcg/mL) | SAR441344 |
|---|---|
| Day 1 (end of infusion) | 466.10 ± 93.86 |
| Day 1 (4 hours post-infusion) | 427.22 ± 102.07 |
| Week 2 (pre-dose) | 139.98 ± 28.30 |
| Week 4 (pre-dose) | 132.91 ± 36.21 |
| Week 6 (pre-dose) | 135.18 ± 46.39 |
| Week 8 (pre-dose) | 141.34 ± 44.85 |
| Week 10 (pre-dose) | 142.25 ± 48.80 |
| Week 12 | 151.59 ± 56.49 |
Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344.
| mcg/mL | SAR441344 |
|---|---|
| Day 1 (end of infusion) | 479.06 (302.4 to 652.2) |
| Day 1 (4 hours post-infusion) | 408.37 (253.1 to 623.6) |
| Week 2 (pre-dose) | 132.21 (98.3 to 203.1) |
| Week 4 (pre-dose) | 133.01 (45.6 to 236.5) |
| Week 6 (pre-dose) | 127.32 (60.2 to 237.5) |
| Week 8 (pre-dose) | 135.10 (76.9 to 284.9) |
| Week 10 (pre-dose) | 134.39 (58.0 to 268.1) |
| Week 12 | 148.11 (64.4 to 306.2) |
Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344. Cmax was assessed by a Bayesian approach using the population PK model.
| mcg/mL | SAR441344 |
|---|---|
| Maximum Plasma Concentration (Cmax) of SAR441344 | 190 ± 54.5 |
Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344. tmax was assessed by a Bayesian approach using the population PK model.
| hours | SAR441344 |
|---|---|
| Time to Maximum Plasma Concentration (Tmax) of SAR441344 | 89.1 (76.8 to 139) |
Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344. AUC0-tau was assessed by a Bayesian approach using the population PK model.
| microgram*hour per milliliter (mcg*h/mL) | SAR441344 |
|---|---|
| Area Under the Curve Over the Dosing Interval (AUC0-tau) of SAR441344 | 57900 ± 18000 |
Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344. t1/2z was assessed by a Bayesian approach using the population PK model.
| hours | SAR441344 |
|---|---|
| Terminal Half-life (t1/2z) of SAR441344 | 662 (374 to 997) |
An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. TEAEs: AEs that occurred, worsened, or became serious during the TEAE period (time from the first IMP administration up to Week 24). Serious adverse events (SAE): Any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or was a congenital anomaly/birth defect. An AESI: an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required.
| Participants | Placebo | SAR441344 |
|---|---|---|
| Any TEAE | 26 | 29 |
| Any TESAE | 1 | 1 |
| Any AESI | 5 | 4 |
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. TEAEs were AEs that occurred, worsened, or became serious during the TEAE period (time from the first IMP administration up to Week 24).
| Participants | Placebo | SAR441344 |
|---|---|---|
| Treatment discontinuation due to TEAEs | 4 | 4 |
| Treatment withdrawal due to TEAEs | 0 | 0 |
For the measurement of local tolerability, participants had a self-evaluation using a VDS before IMP administration, after completion of the IMP administration, and 2 hours post-administration. The participants were asked to report sensations at the injection site and rated the pain severity as following grading: 0= no pain; 1= mild pain; 2= moderate pain, 3= severe pain, 4= very severe. A positive change in VDS score indicated a higher pain severity compared to the pre-dose pain. The numerical change provides the number of grades the pain got worse (positive change) or improved (negative change). Total number of participants with pain intensity increase (change in VDS score of greater than or equal to 1) compared to pre-dose pain intensity are reported.
| Participants | Placebo | SAR441344 |
|---|---|---|
| Week 2: Post-dose versus pre-dose | 7 | 7 |
| Week 2: 2 hours post-dose versus pre-dose | 5 | 8 |
| Week 4: Post-dose versus pre-dose | 12 | 8 |
| Week 4: 2 hours post-dose versus pre-dose | 5 | 6 |
| Week 6: Post-dose versus pre-dose | 13 | 10 |
| Week 6: 2 hours post-dose versus pre-dose | 3 | 3 |
| Week 8: Post-dose versus pre-dose | 7 | 11 |
| Week 8: 2 hours post-dose versus pre-dose | 3 | 1 |
| Week 10: Post-dose versus pre-dose | 7 | 10 |
| Week 10: 2 hours post-dose versus pre-dose | 5 | 1 |
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. Local tolerability at injection site was assessed following IMP injection and findings at the site of injection such as injection site erythema, injection site reaction, and injection site pain were recorded.
| Participants | Placebo | SAR441344 |
|---|---|---|
| Injection site erythema | 1 | 3 |
| Injection site reaction | 2 | 0 |
| Injection site pain | 1 | 0 |
PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Sitting systolic blood pressure (SSBP) less than or equal to (≤)95 millimeters of mercury (mmHg) and decrease from baseline ≥20 mmHg; ≥160 mmHg and increase from baseline ≥20 mmHg; Sitting diastolic blood pressure (SDBP) ≤45 mmHg and decrease from baseline ≥10 mmHg, ≥110 mmHg and increase from baseline ≥10 mmHg; Sitting heart rate (HR) ≤50 beats per minute (bpm) and decrease from baseline ≥20 bpm, ≥120 bpm and increase from baseline ≥20 bpm; Weight ≥5% decrease from baseline, ≥5% increase from baseline.
| Participants | Placebo | SAR441344 |
|---|---|---|
| SSBP: ≤95 mmHg; decrease from baseline ≥20 mmHg | 2 | 2 |
| SSBP: ≥160 mmHg; increase from baseline ≥20 mmHg | 0 | 0 |
| SDBP: ≤45 mmHg; decrease from baseline ≥10 mmHg | 0 | 0 |
| SDBP: ≥110 mmHg; increase from baseline ≥10 mmHg | 0 | 0 |
| Sitting HR: ≤50 bpm; decrease from baseline ≥20 bpm | 1 | 0 |
| Sitting HR: ≥120 bpm; increase from baseline ≥20 bpm | 0 | 0 |
| Weight: ≥5% decrease from baseline | 6 | 3 |
| Weight: ≥5% increase from baseline | 2 | 3 |
PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: HR \<50 bpm, \<40 bpm, \>90 bpm, \>90 bpm and increase from baseline ≥20 bpm, \>100 bpm; PR interval, aggregate \>200 milliseconds (msec), \>200 msec and increase from baseline ≥25%, \>220 msec, \>220 msec and increase from baseline ≥25%, \>240 msec, \>240 msec and increase from baseline ≥25%; QRS duration, aggregate \>110 msec, \>110 msec and increase from baseline ≥25%, \>120 msec, \>120 msec and increase from baseline ≥25%; QT interval, aggregate \>500 msec; corrected QT (QTc) correction method unspecified \>450 msec, \>480 msec, increase from baseline \[30-60\] msec, increase from baseline \>60 msec.
| Participants | Placebo | SAR441344 |
|---|---|---|
| HR: <50 bpm | 2 | 1 |
| HR: <40 bpm | 0 | 0 |
| HR: >90 bpm | 3 | 1 |
| HR: >90 bpm; increase from baseline ≥20 bpm | 1 | 0 |
| HR: >100 bpm | 0 | 0 |
| PR interval, aggregate: >200 msec | 4 | 2 |
| PR interval, aggregate: >200 msec; increase from baseline ≥25% | 1 | 0 |
| PR interval, aggregate: >220 msec | 1 | 0 |
| PR interval, aggregate: >220 msec; increase from baseline ≥25% | 0 | 0 |
| PR interval, aggregate: >240 msec | 1 | 0 |
| PR interval, aggregate: >240 msec; increase from baseline ≥25% | 0 | 0 |
| QRS duration, aggregate: >110 msec | 2 | 0 |
| QRS duration, aggregate: >110 msec; increase from baseline ≥25% | 0 | 0 |
| QRS duration, aggregate: >120 msec | 1 | 0 |
| QRS duration, aggregate: >120 msec; increase from baseline ≥25% | 0 | 0 |
| QT interval, aggregate: >500 msec | 0 | 0 |
| QTc correction method unspecified: >450 msec | 5 | 2 |
| QTc correction method unspecified: >480 msec | 0 | 0 |
| QTc correction method unspecified: Increase from baseline[30-60] msec | 3 | 7 |
| QTc correction method unspecified: Increase from baseline >60 msec | 0 | 0 |
PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Hemoglobin (Hb) ≤115 grams per liter (g/L) (Male \[M\]) or ≤95 g/L (Female \[F\]), ≥185 g/L (M) or ≥165 g/L (F), decrease from baseline ≥20 g/L; Hematocrit ≤0.37 volume per volume (v/v) (M) or ≤0.32 v/v (F), ≥0.55 v/v (M) or ≥0.5 v/v (F); Erythrocytes (red blood cells \[RBC\]) ≥6 x 10\^12 per liter (/L); Platelets \<100 x 10\^9/L, ≥700 x 10\^9/L; Leukocytes (white blood cells \[WBC\]) \<3 x 10\^9/L (Non-Black\[NB\]) or \<2 x 10\^9/L (Black\[B\]), ≥16 x 10\^9/L; Neutrophils \<1.5 x 10\^9/L (NB) or \<1 x 10\^9/L (B); Lymphocytes \>4 x 10\^9/L, \<0.5 x 10\^9L; Monocytes \>0.7 x 10\^9/L; Basophils \>0.1 x 10\^9/L; Eosinophils \>0.5 x 10\^9/L or \>upper limit of normal(ULN) (if ULN ≥0.5 x 10\^9/L).
| Participants | Placebo | SAR441344 |
|---|---|---|
| Hb: ≤115 g/L (M); ≤95 g/L (F) | 0 | 1 |
| Hb: ≥185 g/L (M); ≥165 g/L (F) | 0 | 1 |
| Hb: Decrease from baseline ≥20 g/L | 2 | 2 |
| Hematocrit: ≤0.37 v/v (M); ≤0.32 v/v (F) | 5 | 3 |
| Hematocrit: ≥0.55 v/v (M); ≥0.5 v/v (F) | 0 | 1 |
| RBC: ≥6 x 10^12/L | 0 | 1 |
| Platelets: <100 x 10^9/L | 0 | 0 |
| Platelets: ≥700 x 10^9/L | 0 | 0 |
| WBC: <3 x 10^9/L (NB); <2 x 10^9/L (B) | 8 | 5 |
| WBC: ≥16 x 10^9/L | 0 | 0 |
| Neutrophils: <1.5 x 10^9/L (NB); <1 x 10^9/L (B) | 7 | 7 |
| Lymphocytes: >4 x 10^9/L | 0 | 1 |
| Lymphocytes: <0.5 x 10^9L | 2 | 0 |
| Monocytes: >0.7 x 10^9/L | 1 | 2 |
| Basophils: >0.1 x 10^9/L | 0 | 8 |
| Eosinophils: >0.5 x 10^9/L or >ULN | 1 | 0 |
PCSA values:abnormal values considered medically important by Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by Sponsor.Criteria for PCSA:Sodium≤129 millimoles per liter(mmol/L),≥160 mmol/L;Potassium\<3 mmol/L,≥5.5 mmol/L;Glucose≤3.9 mmol/L and \<lower limit of normal(LLN),≥11.1 mmol/L(unfasted);≥7 mmol/L(fasted); Creatine kinase(CK)\>3 ULN,\>10 ULN;Creatinine≥150 micromoles/L(adults),≥30% change from baseline,≥100% change from baseline;Creatinine clearance(CG)≥60-\<90 milliliters per minute(mL/min)(mild decrease in glomerular filtration rate\[GFR\]),≥30-\<60 mL/min(moderate decrease in GFR),≥15-\<30 mL/min(severe decrease in GFR),\<15 mL/min(end stage renal disease),Urea nitrogen≥17 mmol/L;Alkaline phosphatase(ALP)\>1.5 ULN;Alanine aminotransferase(ALT)\>3 ULN; ALT\>3 ULN and bilirubin\>2 ULN;Aspartate aminotransferase(AST)\>3 ULN;Direct bilirubin\>35% bilirubin and bilirubin\>1.5 ULN;Total bilirubin\>1.5 ULN,\>2 ULN.
| Participants | Placebo | SAR441344 |
|---|---|---|
| Sodium: ≤129 mmol/L | 0 | 0 |
| Sodium: ≥160 mmol/L | 0 | 0 |
| Potassium: <3 mmol/L | 0 | 0 |
| Potassium: ≥5.5 mmol/L | 1 | 0 |
| Glucose: ≤3.9 mmol/L and <LLN | 3 | 5 |
| Glucose: ≥11.1 mmol/L (unfasted); ≥7 mmol/L (fasted) | 3 | 1 |
| CK: >3 ULN | 0 | 1 |
| CK: >10 ULN | 0 | 0 |
| Creatinine: ≥150 micromoles/L (Adults) | 0 | 0 |
| Creatinine: ≥30% change from baseline | 1 | 2 |
| Creatinine: ≥100% change from baseline | 0 | 0 |
| CG: ≥60 - <90 mL/min | 24 | 16 |
| CG: ≥30 - <60 mL/min | 3 | 2 |
| CG: ≥15 - <30 mL/min | 0 | 0 |
| CG: <15 mL/min | 0 | 0 |
| Urea Nitrogen: ≥17 mmol/L | 0 | 0 |
| ALP: >1.5 ULN | 0 | 1 |
| ALT: >3 ULN | 0 | 0 |
| ALT >3 ULN; Bilirubin >2 ULN | 0 | 0 |
| AST: >3 ULN | 0 | 0 |
| Direct Bilirubin >35% Bilirubin; Bilirubin >1.5 ULN | 0 | 0 |
| Total Bilirubin: >1.5 ULN | 0 | 1 |
| Total Bilirubin: >2 ULN | 0 | 0 |
PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Potential of hydrogen (pH) ≤4.6 or ≥8.
| Participants | Placebo | SAR441344 |
|---|---|---|
| pH ≤4.6 | 0 | 0 |
| pH ≥8 | 3 | 2 |
Serum samples were collected at the specified timepoints for the assessment of ADAs to SAR441344. Number of participants with treatment-emergent ADA defined as at least 1 treatment-induced/boosted ADA during the treatment-emergent period, i.e. from the time of the IMP administration up to the end of study visit are reported. Number of participants with positive ADA are reported.
| Participants | SAR441344 |
|---|---|
| Baseline | 2 |
| Week 4 | 2 |
| Week 8 | 2 |
| Week 12 | 0 |
| Week 24 | 5 |
Collected over From first dose of IMP (Day 1) up to end of follow-up period (Week 24). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/42 (0%) | 1/42 (2.4%) | 20/42 (47.6%) |
| SAR441344 | 0/42 (0%) | 1/42 (2.4%) | 15/42 (35.7%) |
| Event | Placebo | SAR441344 |
|---|---|---|
| Osteomyelitis AcuteInfections and infestations | 1/42 | 0/42 |
| Device BreakageProduct Issues | 0/42 | 1/42 |
| Event | Placebo | SAR441344 |
|---|---|---|
| Urinary Tract InfectionInfections and infestations | 6/42 | 1/42 |
| Accidental OverdoseInjury, poisoning and procedural complications | 5/42 | 4/42 |
| Covid-19Infections and infestations | 4/42 | 4/42 |
| NeutropeniaBlood and lymphatic system disorders | 2/42 | 4/42 |
| NasopharyngitisInfections and infestations | 3/42 | 1/42 |
| HeadacheNervous system disorders | 0/42 | 3/42 |
| Abdominal PainGastrointestinal disorders | 3/42 | 0/42 |
| DiarrhoeaGastrointestinal disorders | 3/42 | 0/42 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/42 | 0/42 |
| Injection Site ErythemaGeneral disorders | 1/42 | 3/42 |
Safety population included all randomized participants exposed to the investigational medicinal product (IMP) (regardless of the amount of treatment administered).
| Age, Continuous(years) | Placebo | SAR441344 | Total |
|---|---|---|---|
| Mean | 47.8 ± 12.9 | 49.2 ± 11.1 | 48.5 ± 12.0 |
| Sex: Female, Male(Participants) | Placebo | SAR441344 | Total |
|---|---|---|---|
| Female | 40 | 40 | 80 |
| Male | 2 | 2 | 4 |
| Race/Ethnicity, Customized(Participants) | Placebo | SAR441344 | Total |
|---|---|---|---|
| White | 34 | 28 | 62 |
| Black or African American | 1 | 4 | 5 |
| Asian | 5 | 4 | 9 |
| American Indian or Alaska Native | 1 | 6 | 7 |
| Missing/Not reported | 1 | 0 | 1 |
| EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score(score on a scale) | Placebo | SAR441344 | Total |
|---|---|---|---|
| Mean | 10.38 ± 3.64 | 8.43 ± 3.88 | 9.40 ± 3.87 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Nov 2020 to primary completion in Nov 2023, 35 months.
Results were first posted in Oct 2025, 1 year 11 months after primary completion. A results delay was requested in Nov 2024.
Of 26 phase 2 interventional studies under Sjogren's Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's 35 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Frexalimab